Bio-Technology General wins court ruling on hepatitis-B vaccine.ISELIN, NJ--(BUSINESS WIRE)--June 6, 1997--Bio-Technology General Corp. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :BTGC BTGC Bio-Technology General (stock symbol) BTGC Bukit Tinggi Golf Club (Malaysia) ) today announced that the District Court in Tel-Aviv yesterday dismissed the appeal filed by Biogen, Inc., of a decision by the Israeli Commissioner of Patents which granted BTG's Israeli subsidiary a compulsory license In a compulsory license, a government forces the holder of a patent, copyright, or other exclusive right to grant use to the state or others. Usually, the holder does receive some royalties, either set by law or determined through some form of arbitration. under Biogen's hepatitis-B vaccine patent. The court affirmed the grant of the compulsory license to BTG's Israeli subsidiary. While this decision may be appealed to the Israeli Supreme Court, the license is effective and allows the Company to register and commercialize its third generation hepatitis-B vaccine in Israel and to export it to countries in which Biogen does not have a corresponding patent. Bio-Technology General Corp. develops, manufactures and markets genetically engineered genetically engineered adjective Recombinant, see there and other products for human health care. CONTACT: Investor Relations Investor relations The process by which the corporation communicates with its investors. STRATEGIC GROWTH INTERNATIONAL Don Weinberger 516-829-7111 or BIO-TECHNOLOGY GENERAL CORP. Leah Berkovits 908-632-8800 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion